Schwarz C, Brandt C, Melichar V, Runge C, Heuer E, Sahly H, Schebek M, Koester H, Bouchara JP, Biedermann T, Meissner P, Grosse-Onnebrink J, Skopnik H, Hartl D, Sedlacek L, Tintelnot K (2019)
Publication Type: Journal article
Publication year: 2019
Book Volume: 18
Pages Range: 227-232
Journal Issue: 2
DOI: 10.1016/j.jcf.2018.08.012
Cystic fibrosis (CF) is characterised by chronic airway infection with bacteria and fungi. Infections caused by Scedosporium/Lomentospora species can occur and are difficult to treat. Moulds belonging to the genus Scedosporium/Lomentospora are detected most frequently in respiratory samples of patients with CF, next to Aspergillus spp. Our aim was to define pulmonary fungal infections due to Scedosporium/Lomentospora in CF and to study the antimycotic treatment. In this multicentre study (12 centres; duration January 2008 to December 2014) 31 patients with a lung infection caused by moulds of the genus Scedosporium/Lomentospora were included. 36 courses of antifungal treatment were documented. Scedosporium apiospermum sensu stricto accounted for 48.4% of cases. In 20/31 patients a therapeutic response under antimycotics (median duration 3.9 months) was achieved. Triple and double therapy was significantly more effective compared to monotherapy regarding FEV 1 , radiology, and symptoms. This data suggests that combined treatment is superior to monotherapy in patients with CF.
APA:
Schwarz, C., Brandt, C., Melichar, V., Runge, C., Heuer, E., Sahly, H.,... Tintelnot, K. (2019). Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis. Journal of Cystic Fibrosis, 18(2), 227-232. https://dx.doi.org/10.1016/j.jcf.2018.08.012
MLA:
Schwarz, Carsten, et al. "Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis." Journal of Cystic Fibrosis 18.2 (2019): 227-232.
BibTeX: Download